Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies

Nat Commun. 2022 Feb 14;13(1):864. doi: 10.1038/s41467-022-28578-0.


Patients with hematological malignancies have impaired immune response after two doses of BNT162b2 (Pfizer/BioNTech) vaccine against SARS-CoV-2. Here, in this observational study (registration number HDH F20210324145532), we measure SARS-CoV-2 anti-Spike antibodies, neutralizing antibodies and T-cell responses after immune stimulation with a third dose (D3) of the same vaccine in patients with chronic lymphocytic leukemia (n = 13), B cell non-Hodgkin lymphoma (n = 14), and multiple myeloma (n = 16)). No unexpected novel side effects are reported. Among 25 patients with positive anti-S titers before D3, 23 (92%) patients increase their anti-S and neutralizing antibody titer after D3. All 18 (42%) initially seronegative patients remain negative. D3 increases the median IFN-γ secretion in the whole cohort and induces IFN-γ secretion in a fraction of seronegative patients. Our data thus support the use of a third vaccine dose amongst patients with lymphoid malignancies, even though some of them will still have vaccine failure.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral / immunology
  • BNT162 Vaccine / administration & dosage
  • BNT162 Vaccine / immunology*
  • COVID-19 / immunology
  • COVID-19 / prevention & control
  • COVID-19 / virology
  • Female
  • Hematologic Neoplasms*
  • Humans
  • Immunity, Cellular / immunology*
  • Immunity, Humoral / immunology*
  • Immunization, Secondary / methods*
  • Male
  • Middle Aged
  • Multiple Myeloma
  • SARS-CoV-2 / immunology
  • SARS-CoV-2 / physiology
  • Spike Glycoprotein, Coronavirus / immunology
  • T-Lymphocytes / immunology


  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2
  • BNT162 Vaccine